COVID-19 Public Health Response (Vaccinations) Order 2021

Schedule 3 Vaccinations

cls 4, 9A

Schedule 3: replaced, at 11.59 pm on 25 March 2022, by clause 4 of the COVID-19 Public Health Response (Vaccinations) Amendment Order (No 3) 2022 (SL 2022/77).

ItemDoses of COVID-19 vaccineAdministration requirements
12 doses of Pfizer/BioNTech (Comirnaty, Tozinameran, BNT162b2)

Either—

(a)

both doses received before carrying out certain work; or

(b)

1 dose received before carrying out certain work and the second dose received within 35 days of having the first dose

22 doses of AstraZeneca (Oxford/AstraZeneca, Vaxzevria, AZD1222, ChAdOx1 nCoV-19)

Either—

(a)

both doses received before carrying out certain work; or

(b)

1 dose received before carrying out certain work and the second dose received within 35 days of having the first dose

32 doses of AstraZeneca (Covishield, Serum Institute India formulation)Both doses received before carrying out certain work
42 doses of Moderna (Spikevax, mRNA-1273) Both doses received before carrying out certain work
52 doses of Sinopharm, Beijing (BBIBP-CorV, BIBP vaccine, Covilo)Both doses received before carrying out certain work
62 doses of Sinovac (CoronaVac, PiCoVacc)Both doses received before carrying out certain work
72 doses of Bharat Biotech (Covaxin, BBV152)Both doses received before carrying out certain work
81 dose of Janssen / Johnson & Johnson (Janssen COVID-19 Vaccine, Ad26.COV2.S1, JNJ-78436735)Dose received before carrying out certain work
92 doses of Novavax (Nuvaxovid, NVX-CoC2373)Both doses received before carrying out certain work
102 doses of Covovax (Serum Institute India Novavax formulation)Both doses received before carrying out certain work
11

2 doses of any combination of the following:

  • Pfizer/BioNTech (Comirnaty, Tozinameran, BNT162b2):

  • Moderna (Spikevax, mRNA-1273):

  • AstraZeneca (Oxford/AstraZeneca, Vaxzevria, AZD1222, ChAdOx1 nCoV-19):

  • AstraZeneca (Covishield, Serum Institute India formulation):

  • Sinopharm, Beijing (BBIBP-CorV, BIBP vaccine, Covilo):

  • Sinovac (CoronaVac, PiCoVacc):

  • Bharat Biotech (Covaxin, BBV152):

  • Novavax (Nuvaxovid, NVX-CoC2373):

  • Covovax (Serum Institute India Novavax formulation)

Either—

(a)

both doses received before carrying out certain work; or

(b)

1 dose received before carrying out certain work and the second dose received within 35 days of having the first dose

12

If a person has received 1 or more doses (or for Zydus Cadila or Rasi Cov Pars, 1, 2, or 3 doses) of any of the following, then 1 additional dose of Pfizer/BioNTech, Moderna, AstraZeneca (Vaxzevria or Covishield), or Janssen vaccine is required:

  • Sinopharm, Wuhan (WIBP-CorV. Inactivated Vero Cells):

  • Sputnik V (Gamaleya Research Institute of Epidemiology and Microbiology Gam-COVID-Vac):

  • Gamaleya Research Institute of Epidemiology and Microbiology (Sputnik light):

  • Takeda (TAK-919) (note: this is a Moderna formulation):

  • CanSino (Convidecia, PakVac, Ad5-nCoV):

  • Zydus Cadila (ZyCoV-D):

  • Anhui Zhifei Longcom (Zifivax, ZF2001, ZF-UZ-VAC-2001):

  • Minhai Biotechnology Co (Beijing) (KCONVAC, Minhai COVID-19 vaccine):

  • Shifa Pharmed Industrial Co (COVIran Barekat, BIV1-CoVIran):

  • Federal Budgetary Research Institution State Research Center of Virology and Biotechnology VECTOR FBRI (EpiVacCorona, Aurora-CoV):

  • Chumakov Centre (KoviVac):

  • Khazakstan Research Institute for Biological Safety Problems, RIBSP (QazVac, QazCovid-in):

  • Medigen Vaccine Biologics Corporation, MVC (MVC COVID-19 vaccine, MVC-COV1901):

  • Center for Genetic Engineering and Biotechnology, CIGB (Abdala, CIGB-66):

  • Vaxine/CinnaGen Co COVAX-19 (SpikoGen):

  • Biological E. (BioE) Limited (Corbevax, BECOV2D, BECOV2A, BioE COVID-19):

  • Federal Budgetary Research Institution State Research Center of Virology and Biotechnology VECTOR, FBRI (EpiVacCorona-N, EpiVacCorona):

  • Health Institutes of Turkey (Turkovac, ERUCOV-VAC):

  • Instituto Finlay de Vacunas Cuba (Soberana 02, FINLAY-FR-2, Pasteurcovac):

  • National Vaccine and Serum Institute, China (Recombinant SARS-COV-2 Vaccine (CHO Cell), NVSI-0608, Recombinant COVID-19 Vaccine (CHO cell, NVSI-06-08)):

  • Organization of Defensive Innovation and Research, Iran (FAKHRAVAC, MIVAC):

  • Razi Vaccine and Serum Research Institute, Iran (Rasi Cov Pars)

All doses must be received before carrying out certain work

13

If a person has received 2 doses of Instituto Finlay de Vacunas Cuba (Soberana 02, FINLAY-FR-2, Pasteurcovac) and 1 dose of Instituto Finlay de Vacunas Cuba (Soberana Plus, FINLAY-FR-1A), then 1 additional dose of Pfizer/BioNTech, Moderna, AstraZeneca (Vaxzevria or Covishield), or Janssen vaccine is required

All doses must be received before carrying out certain work